Suppr超能文献

激素疗法对接受前列腺癌调强放射治疗的男性性生活质量的影响。

The impact of hormonal therapy on sexual quality of life in men receiving intensity modulated radiation therapy for prostate cancer.

作者信息

Son Christina H, Chennupati Sravana K, Kunnavakkam Rangesh, Liauw Stanley L

机构信息

Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois.

Department of Radiation Medicine, Oregon Health & Science University, Portland, Oregon.

出版信息

Pract Radiat Oncol. 2015 May-Jun;5(3):e223-e228. doi: 10.1016/j.prro.2014.10.003. Epub 2014 Dec 6.

Abstract

PURPOSE

Sexual function is an important concern in men receiving intensity modulated radiation therapy (IMRT) for prostate cancer. Our aim was to study the impact of IMRT and androgen deprivation therapy (ADT) on sexual function over time and to report the effectiveness of sexual medications or aids.

METHODS AND MATERIALS

A total of 179 men, median age 69, received definitive IMRT for prostate cancer and completed 2 surveys (Expanded Prostate Cancer Index Composite-26 and a sexual medicines/devices survey) for at least 2 time points. Surveys were prospectively collected at baseline (before all therapy), and 2, 6, 12, 18, and 24 months after IMRT. Median dose was 76 Gy to the prostate. ADT was administered to 59% of patients (median duration 5 months, initiated 2 months before IMRT). Global scores were generated for the Expanded Prostate Cancer Index Composite-26 questions. Longitudinal analysis was performed by constructing a generalized estimation equations model, and clinical variables were tested for association with global scores.

RESULTS

Overall, there was a significant decline in global sexual score through 2 years. Men receiving ADT had a lower sexual score at 2 and 6 months, but this difference disappeared at 24 months. Analysis of individual sexual symptoms showed no significant difference at 24 months except that men on ADT were less likely to be sexually active (P = .02); this difference was not observed for men receiving short-term ADT only. Longitudinal analysis revealed that duration of ADT was the only factor associated with global sexual score. Phosphodiesterase inhibitors were attempted by roughly half of all men, with 66% experiencing benefit, whereas other aids were attempted by roughly 5% of men.

CONCLUSIONS

Although ADT adversely affected short-term sexual function, there was no significant difference in global score and most sexual symptoms by 24 months. These data are useful for anticipatory guidance regarding expectations after IMRT.

摘要

目的

性功能是接受前列腺癌调强放射治疗(IMRT)的男性患者的一个重要关注点。我们的目的是研究IMRT和雄激素剥夺治疗(ADT)随时间推移对性功能的影响,并报告性药物或辅助器具的有效性。

方法和材料

共有179名男性,中位年龄69岁,接受了前列腺癌的根治性IMRT,并在至少2个时间点完成了2项调查(扩展前列腺癌指数综合问卷-26和一项性药物/器具调查)。调查在基线(所有治疗前)以及IMRT后的2、6、12、18和24个月前瞻性收集。前列腺的中位剂量为76 Gy。59%的患者接受了ADT(中位持续时间5个月,在IMRT前2个月开始)。针对扩展前列腺癌指数综合问卷-26的问题生成了总体评分。通过构建广义估计方程模型进行纵向分析,并测试临床变量与总体评分的相关性。

结果

总体而言,在2年时间里总体性功能评分显著下降。接受ADT的男性在2个月和6个月时性功能评分较低,但这种差异在24个月时消失。对个体性症状的分析显示,在24个月时没有显著差异,只是接受ADT的男性性活动较少(P = 0.02);仅接受短期ADT的男性未观察到这种差异。纵向分析表明,ADT的持续时间是与总体性功能评分相关的唯一因素。大约一半的男性尝试过磷酸二酯酶抑制剂,其中66%有获益,而大约5%的男性尝试过其他辅助器具。

结论

尽管ADT对短期性功能有不利影响,但到24个月时总体评分和大多数性症状没有显著差异。这些数据对于IMRT后预期情况的前瞻性指导很有用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验